Information for State, Tribal, and Territorial Partners
The Health Partner Ordering Portal (HPOP) is an ordering portal for requesting and ordering COVID-19 therapeutic products provided at no cost by the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. HPOP is used to order Paxlovid and Lagevrio and will be the ordering portal for any future therapeutic products allocated by HHS/ASPR.
As of January 24, 2022, allocations of bamlanivimab/etesevimab and REGEN-COV have been paused following FDA’s revised EUA’s for both products limiting their use due to the prevalence of the omicron variant. Distribution of sotrovimab was paused on April 5, 2022 due to the product’s lack of effectiveness against the Omicron BA.2 variant and distribution of bebtelovimab was paused on November 30, 2022 because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1. Evusheld was paused on January 26, 2023 because the therapeutic is unlikely to be active against more than 90% of the SARS-CoV-2 variants circulating in the U.S.
HPOP onboarding is mandatory for all jurisdictional partners (also known as Central Partners). Please work with your area’s
ASPR Regional Emergency Coordinator to complete the onboarding process.
Each jurisdiction must have at least one administrator to manage the partner and their providers.
User Roles: Partners, Central Partners, Providers, and Contacts
A partner and central partner are the same entity. HPOP is designed around the concept of a central partner managing their providers. A partner is a:
- Jurisdiction - e.g. Florida, California, Guam, District of Columbia
- Federal Retail Pharmacy Therapeutics Partners (FRPTP) - e.g. CVS, Walgreens, Publix, Albertsons
- Federal Entity - e.g. Department of Defense, Department of State, Indian Health Service
A provider is the individual site of care that receives therapeutic products (e.g., CVS store 123, doctor’s office, hospital). Providers are managed and onboarded by the partner.
A contact is the individual HPOP user (e.g., Mr. John Doe, Ms. Jane Smith). Primary contacts are managed by the partner. Other contacts can be added by the provider itself, provided the partner does not disable the feature.
Contact emails must be sent to an individual. You must not use generic or group emails.
The Tiberius platform integrates data sources from federal agencies, jurisdictions, and FRPTPs to create a comprehensive common operating picture for COVID-19 therapeutics planning, distribution, and administration.
Each jurisdiction must have at least one user with Tiberius access.
Contact your ASPR Regional Emergency Coordinator to request an account.
HPOP is for ordering and reporting of inventory/ utilization while Tiberius is used as the analytics platform to view the data collected in HPOP.
How to find out if your facility has an HPOP account
If you would like to confirm or are not sure whether your facility has an HPOP account, contact the CARS Helpdesk:
firstname.lastname@example.org or 833-748-1979 and provide your facility information to obtain the contact information for you partner.
If your facility has an HPOP account
No further action is needed. The therapeutics will be reported into HPOP by the same mechanism Paxlovid, Lagevrio, and Evusheld are reported.
If your facility does not have an HPOP account
Your partner will be able to help set up an account for your facility. HPOP administrators will onboard all therapeutic providers that do not have a HPOP account by November 2, 2022. An account activation email with quick start instructions and partner coordinator information will be sent to the contact designated by their partner.
Day 1 Activities for Partners:
- Complete account activation process.
- Review your current list of providers for the following:
- Are providers active? If not, please activate them.
- Are providers properly categorized “Antiviral” (for Lagevrio and Paxlovid)? If not, categorize them. This is critical for ordering. Any address that is not categorized will NOT show up on the ordering screen.
- Do all providers have a state and/or federal pin? If not, add a state pin. This is required as an identifier for the provider record.
- Do all categorized providers have a primary contact loaded? If not, you must add a primary contact to that provider to allow them to log in.
- Add any missing provider addresses. Review the provider list to ensure the address is actually “missing” before a new one is entered.
Day 1 Activities for Providers:
- Complete account activation process.
- Verify the address.
- Verify the business hours.
- Enter the license number and expiration date (Ex. BOP, medical license, etc.).
Reporting On-Hand Inventory and Utilization Data
Providers will be able to enter inventory and utilization data into HPOP. As noted in the August 10, 2022
guidance update for the reporting of COVID-19 hospital data, reporting inventory of sotrovimab, bamlanivimab/etesevimab (bam/ete), and casirivimab/imdevimab (REGEN-COV) will be moved from the COVID-19 Hospital data collection (currently reported through TeleTracking or state reporting systems) to the Health Partner Ordering Portal (HPOP) Therapeutics starting November 2, 2022, consolidating reporting for all products into one system.
Reporting of all USG supply remains mandatory until all doses delivered are accounted for as administered, wasted (unusable due to damage or expiration), or transferred to another facility. Providers should report the quantities since their last report (not cumulative). Reporting cadence for sotrovimab, bamlanivimab/etesevimab (bam/ete), casirivimab/imdevimab (REGEN-COV), bebtelovimab, and Evusheld will be weekly on Thursdays by 11:59 PM.
Paxlovid and Lagevrio reporting is required twice per week by 11:59 PM Monday and Thursday. HPOP-Therapeutic accounts for providers that have not reported in 90 days will be deactivated. Contact the CARS helpdesk to reactivate.
User guides for HPOP
To learn more about reporting in HPOP, see
Reporting All USG Procured Therapeutics in HPOP. Additional information for partners and providers are posted in HPOP in the Partner and Provider Portals respectively and were distributed to partners.
Requesting Replacement Doses of Bebtelovimab
Beginning on November 30, ASPR paused the fulfillment of any pending requests under the
Bebtelovimab Product Replacement Initiative.
Help Desk and Support
For all issues related to HPOP Therapeutics: HPOP.Support@hhs.gov.
A toll-free number is being set up (to be announced soon).
For other issues or inquiries see:
- Password resets - use the “I forgot my password…” link on the sign-in screen.
- General therapeutic program questions - COVID19.
- Tiberius access or account questions -
- OptumServe -
representatives are available for Tiberius user support and questions.